Evotec (NASDAQ:EVO) Announces Quarterly Earnings Results

Evotec (NASDAQ:EVO) released its earnings results on Wednesday. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.25), FiscalAI reports. Evotec had a negative return on equity of 12.40% and a negative net margin of 13.13%.The firm had revenue of $181.32 million for the quarter, compared to the consensus estimate of $229.83 million.

Here are the key takeaways from Evotec’s conference call:

• Evotec has moved Horizon from announcement into implementation, recording EUR 75m of restructuring provisions in Q1 and targeting ~EUR 75m of structural run?rate savings by end?2027 (20–30% expected to materialize in 2026).
• Q1 revenue was EUR 156.6m and adjusted EBITDA was negative EUR 21.9m, with management citing a non?recurring $25m Sandoz license, FX headwinds and D&PD softness; the company reiterated full?year 2026 guidance (EUR 700–780m revenue; EUR 0–40m adj. EBITDA).
• Leadership was strengthened with appointments of Claire Hinshelwood as CFO, Ingrid Muller as COO and Ashiq H. Khan as CCO to drive financial continuity, operational delivery and commercial execution during the transformation.
• Early commercial indicators improved: proposal activity reached a 12?month high, negative change orders declined, proposal turnaround times shortened and net sales orders were up ~15% year?on?year, supporting management’s expectation of H2 recovery.
• Liquidity remains solid at EUR 444.8m (net cash position) and management expects ~USD 100m of gross proceeds in Q2 from the Gilead acquisition of Tubulis, which will further bolster cash resources.

Evotec Stock Performance

NASDAQ EVO traded down $0.19 on Thursday, hitting $3.05. 98,251 shares of the company were exchanged, compared to its average volume of 131,140. Evotec has a twelve month low of $2.31 and a twelve month high of $4.80. The company’s 50 day moving average price is $2.85 and its 200-day moving average price is $3.22. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.07 and a quick ratio of 1.99.

Hedge Funds Weigh In On Evotec

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP purchased a new stake in shares of Evotec in the fourth quarter valued at $40,000. BNP Paribas Financial Markets boosted its position in Evotec by 62.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock worth $50,000 after acquiring an additional 4,600 shares during the period. Bank of America Corp DE increased its holdings in shares of Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after purchasing an additional 9,289 shares during the period. XTX Topco Ltd lifted its position in shares of Evotec by 25.1% in the fourth quarter. XTX Topco Ltd now owns 18,469 shares of the company’s stock worth $57,000 after purchasing an additional 3,709 shares in the last quarter. Finally, HRT Financial LP acquired a new stake in shares of Evotec during the fourth quarter worth approximately $72,000. Institutional investors and hedge funds own 5.81% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on EVO shares. Wall Street Zen upgraded shares of Evotec from a “sell” rating to a “hold” rating in a research report on Saturday, January 10th. Weiss Ratings upgraded shares of Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, April 24th. Berenberg Bank initiated coverage on shares of Evotec in a research note on Tuesday, February 3rd. They issued a “buy” rating on the stock. Finally, HC Wainwright began coverage on Evotec in a report on Wednesday, April 15th. They issued a “buy” rating and a $7.00 price objective for the company. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.00.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.